13th Conference on ADMET

Holiday Inn Kensington Forum, London, UK (July, 9 - 10, 2018)

SMi presents the 13th Conference on ADMET

Exploring the optimisation of ADMET modelling techniques, preclinical DMPK applications and development of biopharmaceuticals

Conference:  Monday 9th – Tuesday 10th July 2018

Location: Holiday Inn Kensington Forum, London, UK

Website: https://www.smi-online.co.uk/pharmaceuticals/uk/admet

SMi is delighted to announce the 13th annual ADMET conference returning to London on the 9th - 10th July 2018, featuring.

Developments in ADMET and novel technologies determine the properties of a drug candidate in the preclinical stage of drug discovery. Poor ADMET properties are the principal cause for a candidate to fail at any stage of drug development. ADME-Toxicology and Pharmacokinetic studies are the key strategic check-points for pharmaceutical companies to reduce drug discovery cost and minimise production times.

The growing use of ADMET technologies is driving the market growth, which is estimated to reach $14,319.9 Million by 2022, with a CAGR of 10.6% from 2016 to 2022*. The main objective of early prediction of ADME properties of a compound is to increase the success rate of it reaching the development stage.

*Source: http://bit.ly/2hMJcgU